Travere Therapeutics, Inc. (TVTX) company profile
Close on Nov 17, 2026Market cap $4.82BP/E –Yield –
About Travere Therapeutics
Pharmaceutical Preparations, SIC 2834
This biopharmaceutical company identifies, develops, and delivers therapies for rare kidney and metabolic diseases. Its commercial product portfolio includes sparsentan, marketed as FILSPARI, an oral medication approved to reduce the decline of kidney function in adults with primary Immunoglobulin A nephropathy. The company also markets tiopronin tablets, under the brand names Thiola and Thiola EC, to treat cystinuria, a rare genetic disorder that causes recurring kidney stones. Additionally, the company advances clinical-stage candidates such as sparsentan for focal segmental glomerulosclerosis and pegtibatinase for classical homocystinuria. It provides these treatments to patient populations with severe, unmet medical needs.
The company is headquartered in San Diego, California. Beyond its domestic operations, its approved therapies have gained regulatory marketing authorization across member states of the European Union, Iceland, Liechtenstein, Norway, and the United Kingdom, alongside commercial distribution launched in Germany and Austria. The firm also relies on regional partnerships to develop and commercialize treatments across international markets including Japan, South Korea, and Taiwan.
Summary of the business section of Travere Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Travere Therapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 3611 Valley Centre Dr, Suite 300 92130
- Phone
- (888) 969-7879
- Website
- travere.com
- Employees
- 497, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- California
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Diego, California
Stock & identifiers
- Ticker
- TVTX
- Former tickers
- RTRX until Jan 11, 2021
- Exchange
- Nasdaq
- IPO date
- Nov 8, 2012
- Shares outstanding
- 94M, Jul 30, 2026
- Public float
- $1.31B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1438533
- CUSIP
- 89422G107
- ISIN
- US89422G1076
- FIGI
- BBG000P9D6W9
- Share class FIGI
- BBG001SL72C5
- EIN
- 26-2383102
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eric M. Dube | CHIEF EXECUTIVE OFFICER, Director | 432,886 |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | 117,066 |
| Elizabeth E. Reed | Chief Legal Officer and GC | 142,889 |
| Jula Inrig | EVP, Head of R&D & CMO | 102,491 |
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 47,728 |
| William E. Rote | Chief Research Officer | 98,197 |
| Christopher R. Cline | CHIEF FINANCIAL OFFICER | 87,908 |
| Jeffrey A. Meckler | Director | 109,800 |
| Gary A. Lyons | Director | 62,400 |
| Roy D. Baynes | Director | 46,000 |
| Timothy Coughlin | Director | 56,250 |
| Brinkley Ruth Williams | Director | 29,750 |
| Suzanne Louise Bruhn | Director | 32,750 |
| Ron Squarer | Director | 39,375 |
| Sandra Poole | Director | 34,000 |
| John A. Orwin | Director | 39,375 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 | $8.46M | $24.50M | $2.45M | $140 | $125 |
| FY2025 | $5.20M | $10.95M | $1.55M | $123 | $118 |
| FY2024 | $7.57M | $885.49K | $2.01M | $63 | $119 |
| FY2023 | $5.75M | $687.24K | $2.24M | $148 | $114 |
| FY2022 | $5.74M | $6.56M | $2.14M | $219 | $126 |
| FY2021 | $5.45M | $10.29M | $1.64M | $192 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Eric Dube, Ph.D. President, Chief Executive Officer and Director | $854.25K | $3.31M | $3.31M | $964.13K | $14.87K | $8.46M | +62% |
| Christopher Cline Chief Financial Officer | $522.92K | $583.11K | $738.25K | $393.75K | $12.89K | $2.25M | +50% |
| Peter Heerma Chief Commercial Officer | $527.92K | $583.11K | $738.25K | $397.50K | $14.98K | $2.26M | +49% |
| Jula Inrig, M.D. Chief Medical Officer | $568.08K | $757.02K | $1.27M | $429.00K | $14.69K | $3.04M | +81% |
| William E. Rote, Ph.D. Chief Research Officer | $522.33K | $583.11K | $738.25K | $393.00K | $19.77K | $2.26M | +49% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of January 31, 2026, we had 497 full-time employees, with most of those based in the United States and a small number outside of the United States.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?